A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer

A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer

<b>Background/Objectives</b>: Regulatory T cells (Treg) suppress immunity in the tumor microenvironment, are linked to poor prognosis across breast cancer subtypes, and suppress the cytolytic function of cytotoxic CD8+ T cells. Denileukin diftitox, a diphtheria toxin (DT)/IL-2 fusion pro...

Full description

Saved in:
Bibliographic Details
Main Authors: William R. Gwin, Lupe G. Salazar, James Y. Dai, Doreen Higgins, Andrew L. Coveler, Jennifer S. Childs, Rosie Blancas, Yushe Dang, Jessica Reichow, Meredith Slota, Hailing Lu, Mary L. Disis
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Vaccines
Subjects:
denileukin diftitox
regulatory T-cells
breast cancer
immunity
tumor microenvironment
Online Access:https://www.mdpi.com/2076-393X/13/2/117
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items